ArticleJournal of nanobiotechnology2026
Macrophage exosome-modified Mn/Se nanoheterostructure induces post-infarction cardiomyocyte regeneration and immunometabolic microenvironment repair.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Myocardial infarction (MI) is the most lethal cardiovascular disease and poses a critical threat to global health. While current MI therapies partially improve cardiac function, advanced precision therapies with translational potential capable of interrupting the vicious pathological cycles remain a pivotal challenge to be addressed. Here, based on a Mn/Se nanoheterostructure that meets human elemental requirements, we constructed a PMS@ME nanotherapeutic system for achieving efficient post-MI repair. Polydopamine was incorporated to synergistically enhance biocompatibility and therapeutic efficacy. The surface is modified with exosomes derived from macrophages that highly express adhesion receptors, enabling precise targeting to the myocardial injury area. PMS@ME administration promotes cardiomyocyte survival, extracellular repair, and mitochondrial homeostasis, while suppressing oxidative damage and immune-inflammatory disorders, achieving preserved cardiac function. Importantly, PMS@ME can induce cardiomyocyte to restart the cell cycle and promotes post-MI cardiomyocyte regeneration by inhibiting the Hippo signaling pathway. These findings demonstrate the potential of the PMS@ME system in MI treatment, offering a blueprint for designing multifunctional nanotherapies tailored to human elemental essentials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.